Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

Pittsburgh biotech firms see potential benefits from upcoming tariffs and reshoring efforts, despite uncertainties in NIH ...